Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen CEO Steps Down as Company Restates Q2 Earnings, Posts 16-Percent Decline in Q3 Revenues

NEW YORK, Dec. 21 (GenomeWeb News) - Ciphergen Biosystems today restated its second-quarter earnings to reflect the "improper recognition" of $552,000 in revenues that its audit committee identified in mid-November.

The company also reported a 16-percent decline in its third-quarter revenues and announced several executive management changes.

Effective Dec. 31, William Rich will retire as CEO and as a member of the company's board of directors, while Gail Page will be promoted from president and COO to president and CEO and a member of the board. In addition, James Rathmann has been appointed executive chairman of the company and John Young will act as lead outside director.

"The restatement was a distracting event for the company, but we have been making appropriate changes to our internal controls and we are now focused on moving forward with the business," Page said in a statement.

For the second quarter of 2005, which ended June 30, Ciphergen reported restated revenues of $6.9 million as compared to the previously reported $7.5 million. The company said that the adjustment caused its reported net loss for the period to increase by $354,000 to $9.4 million.

For the third quarter of 2005, which ended Sept. 30, Ciphergen's total revenue fell to $7.1 million from $8.5 million in the third quarter of 2004.

The company's third-quarter R&D spending fell year-over-year to $3.1 million from $4.3 million in the third quarter of 2004.

Ciphergen narrowed its third-quarter net loss to $7.5 million from $9.5 million in the third quarter of 2004.

As of Sept. 30, Ciphergen had $28.9 million in cash and cash equivalents.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.